February 2026 Research Update

This month added clearer, longer-term information about BTK inhibitors (a targeted treatment class that includes zanubrutinib and ibrutinib) in Waldenstrom macroglobulinemia. In a large head-to-head trial, zanubrutinib generally produced deeper responses sooner than ibrutinib and had fewer treatment stops due to side effects, while both treatments were still associated with some risks. Smaller reports added detail about what uncommon effects can look like in real life and how neurological symptoms tied to IgM antibodies might improve in an individual patient receiving zanubrutinib with IVIg. [1] [2] [3]

With longer follow-up from the ASPEN phase III trial, very good partial response or complete response rates continued to rise over time and stayed numerically higher with zanubrutinib than with ibrutinib at each reported time point. The time to reach a very deep response was shorter with zanubrutinib (median 6.7 months) than with ibrutinib (median 16.6 months), and fewer people stopped zanubrutinib due to side effects than ibrutinib. These results help some patients understand why two drugs in the same class may still feel different in how quickly they work and how tolerable they are over time. [1]

The same trial also described safety differences that may matter to patients who worry about long-term side effects. Cardiovascular problems such as atrial fibrillation/flutter were reported more often with ibrutinib, while low neutrophil counts (a type of white blood cell) were more common with zanubrutinib in the main comparison cohort. The trial also explored whether gene changes such as CXCR4 and TP53 might relate to outcomes, but those subgroup findings were presented as exploratory and not a simple rule for individual prediction. [1]

Two case reports added practical detail about less common situations that large trials may not fully capture. One patient developed a mild acne-like rash within days of starting zanubrutinib that cleared over about 4 weeks while staying on the drug. Another patient with a rare WM-associated nerve problem (CANDA) had sustained clinical and nerve-testing improvement after starting zanubrutinib while continuing IVIg, alongside a drop in IgM paraprotein even though some antibodies remained detectable. [2] [3]

For many patients, the most directly relevant update this month is that longer-term trial follow-up continued to show a pattern of deeper responses and fewer treatment discontinuations with zanubrutinib compared with ibrutinib, along with different side-effect profiles. This may matter now for understanding what outcomes and side effects have been observed in large groups, but it does not by itself determine what any one person will experience. The single-patient reports mainly add awareness: BTK inhibitors can cause unusual effects like acneiform rash, and in a rare antibody-related nerve condition, improvement was reported in one person using zanubrutinib with IVIg. What remains uncertain is how often these specific individual experiences occur and which patients are most likely to see them. [1] [2] [3]

This month included a real-world snapshot of how Waldenstrom macroglobulinemia has been treated in one center over many years, with outcomes that appeared broadly similar to reports from other regions. The main pattern was that chemo-immunotherapy combinations were commonly used as first treatment, and many patients achieved a response. The report also highlighted that the MYD88 mutation rate in the tested subgroup was lower than often reported elsewhere, without an obvious signal of markedly different overall outcomes in this series. [4]

In this single-center series of 55 patients treated between 2009 and 2023, chemo-immunotherapy was the most common front-line approach, most often bendamustine plus rituximab. The overall response rate was 78.2% and the major response rate was 69.1% during a median follow-up of 30 months, with survival and time-to-next-treatment measures also reported. MYD88 testing was done in 30 patients and 53.3% were positive, which the authors described as comparatively low for WM. [4]

For patients and caregivers, this kind of real-world study can help set expectations about what treatments are commonly used in routine care and what kinds of response rates have been reported outside of clinical trials. It may matter now as background context, especially for people comparing different health systems or treatment eras, but it is not designed to prove that one regimen is better than another. What remains uncertain is how much these results apply to other centers, since choices of therapy, access to drugs, and patient characteristics can differ across regions and time periods. [4]

This month, studies on diagnosis and population trends pointed in a consistent direction: WM is being identified more often in populations, and careful lab testing remains important because WM-related proteins can sometimes be missed or discovered only after extended evaluation. Registry data from Australia showed increasing incidence and prevalence over time, with a 10-year survival estimate reported for WM. Case-based reports emphasized that standard blood protein testing can be crucial for finding WM during an anemia workup, and that certain lab methods can sometimes fail unless special sample handling is used. [5] [6] [7]

In the Australian registry analysis (707 WM cases from 2009 to 2018 across four states), both the incidence and prevalence of WM increased over the study period, and projected trends suggested continuing increases into the future. The reported 10-year survival for WM was about 42%, and older age was linked with higher mortality risk, while annual mortality could not be robustly calculated because follow-up time was limited. This helps explain why some communities may see more people living with WM over time, even when individual experiences vary widely. [5]

Two clinical case reports highlighted how WM can show up in everyday diagnostic pathways and how lab testing can be tricky. One report described an older adult with persistent unexplained anemia where expanded blood tests (including serum protein electrophoresis and immunoglobulin testing) ultimately revealed WM. Another report described a patient with extremely high IgM in whom a common lab method repeatedly failed to show the monoclonal protein until a specific pretreatment (beta-mercaptoethanol) was used, suggesting cryoglobulin-related interference. [6] [7]

A large pooled cohort analysis also examined type 2 diabetes as a risk factor for blood cancers and reported an inverse association with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia compared with people without diabetes. The authors noted that some inverse findings were unexpected and need further investigation. For WM specifically, this finding is best viewed as a population-level observation that does not explain why any one person develops WM. [8]

Together, these studies may matter now mostly by improving understanding rather than changing care. Registry results support the idea that WM is becoming more common in the population and that age plays an important role in outcomes, which can affect how patients think about the broader WM community and long-term planning. The case reports reinforce a practical point: WM can be uncovered during evaluation of persistent anemia, and laboratory methods sometimes need special handling when IgM behaves unusually in the test system. What remains uncertain is how often these diagnostic problems occur and how best to predict them in advance, because the evidence here includes single-patient reports and registry data with limited detail on individual health factors. [5] [6] [7] [8]

An early clinical study this month tried to explain why some people do well on ibrutinib for a long time while others progress, focusing on detailed changes inside the bone marrow over time. The main pattern was that WM cells did not all follow the same evolutionary path during treatment, and those paths were linked to whether disease control lasted or not. The study also reported changes in immune cells that appeared different in people who progressed. [9]

In this small phase II trial of ibrutinib in 17 previously untreated patients, researchers identified three clonal patterns during treatment: evolution, devolution, and no-evolution. The evolution pattern was linked to progression, while devolution was linked to durable response, and a baseline score (the WIP score) was reported to predict response at the start of therapy. The study also pointed to LYN as a possible driver of resistance in WM cells, and described a pattern of CD8 T-cell dysfunction in patients who progressed. [9]

For patients, this study mainly matters as research that aims to make treatment response more predictable in the future. It suggests that WM can change in different ways under ibrutinib, and that measuring certain baseline features might someday help forecast who is more likely to have a durable response. What remains uncertain is whether the proposed prediction score and resistance signals will work reliably in larger and more diverse patient groups, and how these findings would translate into real-world decisions. [9]